Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cidara Therapeutics

44.95
+23.93113.84%
Pre-market: 47.622.67+5.95%09:08 EDT
Volume:6.74M
Turnover:276.45M
Market Cap:582.99M
PE:-1.68
High:45.39
Open:40.63
Low:37.76
Close:21.02
Loading ...

BRIEF-Cidara Therapeutics Announces Positive Topline Results From Its Phase 2B Navigate Trial

Reuters
·
Yesterday

Cidara Therapeutics Inc - Study Meets Primary and Secondary Efficacy Endpoints

THOMSON REUTERS
·
Yesterday

Cidara Therapeutics Announces Positive Topline Results From Its Phase 2B Navigate Trial Evaluating Cd388, a Non-Vaccine Preventative of Seasonal Influenza

THOMSON REUTERS
·
Yesterday

Cidara Therapeutics Inc - Cd388 Well-Tolerated With No Safety Signals Observed

THOMSON REUTERS
·
Yesterday

Cidara Therapeutics Inc - Cd388 Doses Show 76%, 61%, and 58% Protection From Influenza

THOMSON REUTERS
·
Yesterday

Cidara Therapeutics Inc. Concluded Annual Stockholders Meeting

Reuters
·
21 Jun

Director’s Bold Move: A Major Investment in Cidara Therapeutics!

TIPRANKS
·
05 Jun

Director Chrysa Mineo Reports Acquisition of Common Shares in Cidara Therapeutics Inc

Reuters
·
05 Jun

Cidara Therapeutics Is Maintained at Buy by Needham

Dow Jones
·
04 Jun

Citizens JMP Keeps Their Buy Rating on Cidara Therapeutics (CDTX)

TIPRANKS
·
02 Jun

Strong Buy Rating for Cidara Therapeutics: CD388’s Revolutionary Potential in Flu Treatment and Beyond

TIPRANKS
·
30 May

Cidara Therapeutics price target raised to $35 from $31 at RBC Capital

TIPRANKS
·
23 May

Cidara Therapeutics Price Target Maintained With a $35.00/Share by Needham

Dow Jones
·
23 May

Analysts Are Bullish on These Healthcare Stocks: Cidara Therapeutics (CDTX), Merus (MRUS)

TIPRANKS
·
23 May

RBC Raises Price Target on Cidara Therapeutics to $35 From $31, Keeps Outperform, Speculative Risk

MT Newswires Live
·
23 May

Cidara Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
16 May

Cidara Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Chief Medical Officer Nicole Negar Davarpanah

Reuters
·
13 May

Cidara Therapeutics’ CD388 Progress and Challenges Highlighted in Earnings Call

TIPRANKS
·
10 May

Cidara Therapeutics Is Maintained at Market Outperform by JMP Securities

Dow Jones
·
09 May

RBC Cuts Price Target on Cidara Therapeutics to $31 From $34, Keeps Outperform, Speculative Risk

MT Newswires Live
·
09 May